Parameter1 | | Adj. Odds | S.E OR | 95% CI | P-value2 |
---|
Sex | Female | Reference | – | – | 0.400 |
Male | 0.707 | 0.412 | 0.315 to 1.585 | |
Age (yr) | > 55 | Reference | – | – | 0.055 |
≤ 55 | 2.064 | 0.397 | 0.983 to 4.336 | |
DM | No | Reference | – | – | 0.219 |
Yes | 1.650 | 0.407 | 0.743 to 3.663 | |
Tobacco | No | Reference | – | – | 0.194 |
Yes | 0.596 | 0.399 | 0.272 to 1.303 | – |
Plt (× 109/L) | ≤ 150 | Reference | – | – | 0.109 |
< 150 | 2.023 | 0.451 | 0.836 to 4.894 | – |
NLR | ≤ 2.5 | Reference | – | – | 0.429 |
> 2.5 | 1.408 | 0.435 | 0.600 to 3.304 | – |
AgI | Score = 4 | Reference | – | – | 0.021 |
Score 5–8 | 2.469 | 0.801 | 0.514 to 11.857 | – |
Score > 8 | 6.919 | 0.873 | 1.249 to 38.332 | – |
- 1Overall Model was applied while considering HCV treatment naïve patients as reference 2 P-value < 0.05 was considered as significant
- HCV Hepatitis-C Virus; HCC Hepatocellular carcinoma; DM Diabetes Mellitus; Plt Platelet count; NLR Neutrophil to lymphocyte ratio; AgI Aggressiveness Index (sum of score) = Maximum Tumor Diameter (MTD) (in tertiles): MTD < 4.5; 4.5 = MTD = 9.6; MTD > 9.6; scores 1, 2, 3 respectively; Alpha-fetoprotein (AFP) (cut-off): AFP < 100; 100 = AFP = 1000; AFP > 1000; scores 1, 2, 3 respectively; Portal Vein Thrombosis (PVT) (no/yes): PVT (no); PVT (yes); scores 1, 3 respectively; nodules (number): Nodules = 3; nodules > 3; scores 1, 3 respectively